Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer
Status:
Completed
Trial end date:
2018-09-19
Target enrollment:
Participant gender:
Summary
The purpose of the study is to compare the efficacy and safety of 2 doses of drug AZD2281
against liposomal doxorubicin to see which is effective and well tolerated in treating
patients with measurable BRCA1- or BRCA2-positive advanced ovarian cancer and who have failed
previous platinum therapy.